ARG1

Across TCGA pan-cancer cohorts, ARG1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARG1 data layer compared with 16 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARG1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARG1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where ARG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.916	0.580	.007	34	view →
LUAD	OS	Tertile	III,IV	0.216	0.672	.004	12	view →
PDAC	OS	Quartile	III,IV	0.134	0.868	.006	8	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.599	.034	4	view →
HNSC	OS	Quartile	IV	0.965	0.694	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARG1–CCRCC (DFS)

Open the CCRCC breakdown →